SIGA (SIGA) 10-Q 3 Nov 22 2022 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Oct. 21, 2022
Document Information [Line Items]
Entity Central Index Key	0001010086
Entity Registrant Name	Siga Technologies INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	0-23047
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	13-3864870
Entity Address, Address Line One	31 East 62nd Street
Entity Address, Postal Zip Code	10065
Entity Address, City or Town	New York
Entity Address, State or Province	NY
City Area Code	212
Local Phone Number	672-9100
Title of 12(b) Security	common stock, $.0001 par value
Trading Symbol	SIGA
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		73,024,147

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 109,749,555	$ 103,138,819
Accounts receivable	54,925,558	83,650,450
Inventory	31,261,346	19,510,379
Prepaid expenses and other current assets	964,065	2,453,444
Total current assets	196,900,524	208,753,092
Property, plant and equipment, net	1,979,517	2,365,957
Deferred income taxes, net	4,183,886	2,422,607
Goodwill	898,334	898,334
Other assets	261,814	286,585
Total assets	204,224,075	214,726,575
Current liabilities
Accounts payable	2,445,390	2,028,004
Accrued expenses and other current liabilities	15,887,359	9,252,812
Income tax payable	9,123,153	19,207,042
Total current liabilities	27,455,902	30,487,858
Warrant liability	0	6,521,441
Other liabilities	3,630,046	3,402,869
Total liabilities	31,085,948	40,412,168
Commitments and contingencies
Stockholders’ equity
Common stock ($.0001 par value, 600,000,000 shares authorized, 73,024,147 and 73,543,602, issued and outstanding at September 30, 2022 and December 31, 2021, respectively)	7,302	7,354
Additional paid-in capital	233,271,351	226,070,308
Accumulated deficit	(60,140,526)	(51,763,255)
Total stockholders’ equity	173,138,127	174,314,407
Total liabilities and stockholders’ equity	$ 204,224,075	$ 214,726,575

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	600,000,000	600,000,000
Common stock, shares issued (in shares)	73,024,147	73,543,602
Common stock, shares outstanding (in shares)	73,024,147	73,543,602

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenues
Total revenues	$ 72,211,127	$ 4,846,172	$ 99,417,471	$ 18,313,206
Operating expenses
Cost of sales and supportive services	3,948,974	83,276	9,551,186	1,330,114
Selling, general and administrative	19,656,138	4,471,640	29,241,565	14,113,384
Research and development	5,732,982	3,235,145	16,119,858	7,801,901
Total operating expenses	29,338,094	7,790,061	54,912,609	23,245,399
Operating income/(loss)	42,873,033	(2,943,889)	44,504,862	(4,932,193)
Gain/(loss) from change in fair value of warrant liability	0	(1,066,522)	400,663	294,548
Other income, net	258,975	26,252	354,670	76,055
Income/(loss) before income taxes	43,132,008	(3,984,159)	45,260,195	(4,561,590)
(Provision)/benefit for income taxes	(10,091,420)	870,801	(10,543,595)	805,328
Net and comprehensive income/(loss)	$ 33,040,588	$ (3,113,358)	$ 34,716,600	$ (3,756,262)
Basic income/(loss) per share (in dollars per share)	$ 0.45	$ (0.04)	$ 0.48	$ (0.05)
Diluted income/(loss) per share (in dollars per share)	$ 0.45	$ (0.04)	$ 0.47	$ (0.05)
Weighted average shares outstanding: basic (in shares)	73,024,147	74,840,846	72,924,178	75,822,713
Weighted average shares outstanding: diluted (in shares)	73,259,272	74,840,846	73,616,837	76,634,963
Product Sales and Supportive Services [Member]
Revenues
Total revenues	$ 65,621,511	$ 2,346,110	$ 81,558,148	$ 12,793,615
Research and Development [Member]
Revenues
Total revenues	$ 6,589,616	$ 2,500,062	$ 17,859,323	$ 5,519,591

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net income (loss)	$ 34,716,600	$ (3,756,262)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and other amortization	386,440	393,667
Gain on change in fair value of warrant liability	(400,663)	(294,548)
Stock-based compensation	1,092,893	957,320
Write down of inventory, net	168,446	548,551
Deferred income taxes, net	(1,761,279)	(408,233)
Changes in assets and liabilities:
Accounts receivable	28,724,892	(482,561)
Inventory	(11,919,413)	(9,956,076)
Prepaid expenses and other assets	1,514,150	(139,984)
Accounts payable, accrued expenses and other liabilities	914,139	9,095,055
Income tax payable	(10,083,889)	(871,298)
Deferred revenue	6,364,971	306,443
Net cash provided by/(used in) operating activities	49,717,287	(4,607,926)
Cash flows from investing activities:
Capital expenditures	0	(24,424)
Cash used in investing activities	0	(24,424)
Cash flows from financing activities:
Payment of employee tax obligations for common stock tendered	(12,533)	(173,918)
Repurchase of common stock	(10,149,704)	(20,264,547)
Payment of dividend	(32,944,314)	0
Cash used in financing activities	(43,106,551)	(20,438,465)
Net increase/(decrease) in cash and cash equivalents	6,610,736	(25,070,815)
Cash and cash equivalents at the beginning of period	103,138,819	117,890,240
Cash and cash equivalents at end of period	109,749,555	92,819,425
Supplemental disclosure of non-cash financing activities:
Conversion of warrant to common stock	$ 6,120,778	$ 0

Note 1 - Condensed Consolidated

Note 1 - Condensed Consolidated Financial Statements	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Condensed Consolidated Financial Statements The financial statements of SIGA Technologies, Inc. (“we,” “our,” “us,” “SIGA” or the “Company”) are presented in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the “SEC”) for quarterly reports on Form 10 December 31, 2021 2021 10 March 3, 2022 ( "2021 10 not 2021 10 2021 not three nine September 30, 2022 not

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Revenue Recognition The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers 606” September 30, 2022 Note 3 five five September 30, 2022 not three Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606. Contract modifications may not The Company’s performance obligations are satisfied over time as work progresses or at a point in time. All of the Company’s revenue related to current research and development performance obligations is recognized over time, because the customer simultaneously receives and consumes the benefits provided by the services as the Company performs these services. The Company recognizes revenue related to these services based on the progress toward complete satisfaction of the performance obligation and measures this progress under an input method, which is based on the Company’s cost incurred relative to total estimated costs. Under this method, progress is measured based on the cost of resources consumed (i.e., cost of third third Contract Balances The timing of revenue recognition, billings and cash collections may September 30, 2022 nine September 30, 2022 Repurchase of shares When shares recognized as equity are repurchased, the amount of the consideration paid, which includes directly attributable costs, is recognized as a deduction from equity. The excess of the purchase price above par value of repurchased shares that are retired is presented as an increase to accumulated deficit (or a reduction of retained earnings, if any).

Note 3 - Procurement Contracts

Note 3 - Procurement Contracts and Research Agreements	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Procurement Contract and Research Agreements [Text Block]	3. 19C On September 10, 2018, September 30, 2022 "19C five may ten 19C The base period of performance specifies potential payments of approximately $51.7 million for the following activities: payments of approximately $11.1 million for the delivery of approximately 35,700 courses of oral TPOXX® to the Strategic Stockpile; payments of $8.0 million for the manufacture of 20,000 courses of final drug product of IV TPOXX® ("IV FDP"), of which $3.2 million of payments are related to the manufacture of bulk drug substance ("IV BDS") to be used in the manufacture of IV FDP; payments of approximately $32.0 million to fund advanced development of IV TPOXX®; and payments of approximately $0.6 million for supportive procurement activities. As of September 30, 2022 December 31, 2021, nine September 30, 2022 The options that have been exercised to date provide for payments up to approximately $268.9 million. There are exercised options for the following activities: payments up to $11.2 million for the procurement of raw materials used in the 2020 September 30, 2022 September 30, 2022; Unexercised options specify potential payments up to approximately $281.9 million in total (if all such options are exercised). There are options for the following activities: payments of up to $225.1 million for the delivery of oral TPOXX® to the Strategic Stockpile; payments of up to $51.2 million for the manufacture of courses of IV FDP, of which up to $20.5 million of payments would be paid upon the manufacture of IV BDS to be used in the manufacture of IV FDP; and payments of up to approximately $5.6 million for supportive procurement activities. The options related to IV TPOXX® are divided into two may none 19C three three not one three one three 2022. 64,000 Revenues in connection with the 19C 19C three September 30, 2022 2021 nine September 30, 2022 2021 nine September 30, 2022 no three September 30, 2022 three nine September 30, 2021 U.S. Department of Defense Procurement Contracts On May 12, 2022, #1" #1 second 2022, #1. third 2022, September 2022. On September 28, 2022, #2" #2 International Procurement Contracts This year, through October 31, 2022, 13 March 31, 2024, nine September 30, 2022. On January 13, 2021, five March 2022 July 2022, 2022, No first six 2022. three September 30, 2022, third 2022, On April 3, 2020, four 2022, No first nine 2022. September 30, 2022 The above-listed contract awards were coordinated between SIGA and Meridian under the international promotion agreement (as amended, the "International Promotion Agreement") that was entered into by the parties on June 3, 2019. Under the terms of the International Promotion Agreement, Meridian was granted exclusive rights to market, advertise, promote, offer for sale, or sell oral TPOXX® in a field of use specified in the International Promotion Agreement in all geographic regions except for the United States (the “Territory”), and Meridian has agreed not The fee Meridian retains pursuant to the International Promotion Agreement is a specified percentage of the collected proceeds of sales of oral TPOXX® net of certain expenses, for calendar years in which customer collected amounts net of such expenses are less than or equal to a specified threshold, and a higher specified percentage of such collected net proceeds for calendar years in which such net collected amounts exceed the specified threshold. It is probable that we will exceed the specified threshold in 2022 2022. Revenue in connection with international procurement contracts for the delivery of product are recognized at a point in time on a gross basis, as the Company acts as the principal in the transaction. During the three nine September 30, 2022 three nine September 30, 2021 Research Agreements and Grants In July 2019, January 31, 2025. September 30, 2022 three September 30, 2022 2021 nine September 30, 2022 2021 Contracts and grants include, among other things, options that may may not may not

Note 4 - Inventory

Note 4 - Inventory	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Inventory Disclosure [Text Block]	4. Inventory Inventory includes costs related to the manufacture of TPOXX®. Inventory consisted of the following: As of September 30, 2022 December 31, 2021 Raw materials $ 22,047 $ 22,047 Work in-process 25,075,163 17,453,358 Finished goods 6,164,136 2,034,974 Inventory $ 31,261,346 $ 19,510,379

Note 5 - Property, Plant and Eq

Note 5 - Property, Plant and Equipment	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. Property, Plant and Equipment Property, plant and equipment consisted of the following: As of September 30, 2022 December 31, 2021 Leasehold improvements $ 2,420,028 $ 2,420,028 Computer equipment 471,286 511,062 Furniture and fixtures 347,045 377,859 Operating lease right-of-use assets 3,678,647 3,678,647 6,917,006 6,987,596 Less - accumulated depreciation and amortization (4,937,489 ) (4,621,639 ) Property, plant and equipment, net $ 1,979,517 $ 2,365,957 Depreciation and amortization expense on property, plant, and equipment was $0.4 million for each of the nine September 30, 2022 2021

Note 6 - Accrued Expenses and O

Note 6 - Accrued Expenses and Other Current Liabilities	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Accrued Expenses and Other Liabilities [Text Block]	6. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following: As of September 30, 2022 December 31, 2021 Deferred revenue $ 10,129,667 $ 3,764,696 Compensation 1,997,717 2,811,700 Research and development vendor costs 1,107,791 256,397 Professional fees 900,205 527,026 Other 852,370 938,082 Lease liability, current portion 519,198 466,830 Inventory 380,411 488,081 Accrued expenses and other current liabilities $ 15,887,359 $ 9,252,812

Note 7 - Financial Instruments

Note 7 - Financial Instruments	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Financial Instruments Disclosure [Text Block]	7. Financial Instruments 2016 On September 2, 2016, 2020. September 2, 2016 ten December 31, 2021. In the second 2022, September 30, 2022 Note 8 nine September 30, 2022 As of December 31, 2021, 1.21%; no

Note 8 - Fair Value of Financia

Note 8 - Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Fair Value Disclosures [Text Block]	8. Fair Value of Financial Instruments The carrying value of cash equivalents, accounts receivable, accounts payable, accrued expenses and other current liabilities, and income tax payable approximates fair value due to the relatively short maturity of these instruments. Prior to being fully exercised, common stock warrants, which were classified as a liability, were recorded at their fair market value as of each reporting period. The measurement of fair value requires the use of techniques based on observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our market assumptions. The inputs create the following fair value hierarchy: • Level 1 • Level 2 not • Level 3 third There were no nine September 30, 2022 September 30, 2022 December 31, 2021 1 September 30, 2022 2 2 December 31, 2021 The following table presents changes in the liability-classified warrant measured at fair value using Level 3 Fair Value Measurements of Level 3 liability-classified warrant Warrant liability at December 31, 2021 $ 6,521,441 Decrease in fair value of Warrant liability (400,663 ) Exercise of Warrant (6,120,778 ) Warrant liability at September 30, 2022 $ -

Note 9 - Per Share Data

Note 9 - Per Share Data	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Earnings Per Share [Text Block]	9. Per Share Data The Company computes, presents and discloses earnings per share in accordance with the authoritative guidance, which specifies the computation, presentation and disclosure requirements for earnings per share of entities with publicly held common stock or potential common stock. The objective of basic EPS is to measure the performance of an entity over the reporting period by dividing income (loss) by the weighted average shares outstanding. The objective of diluted EPS is consistent with that of basic EPS, except that it also gives effect to all potentially dilutive common shares outstanding during the period. The following is a reconciliation of the basic and diluted loss per share computation: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Net income/(loss) for basic earnings per share $ 33,040,588 $ (3,113,358 ) $ 34,716,600 $ (3,756,262 ) Less: Change in fair value of warrants — — 400,663 294,548 Net income/(loss), adjusted for change in fair value of warrants for diluted earnings per share $ 33,040,588 $ (3,113,358 ) $ 34,315,937 $ (4,050,810 ) Weighted-average shares 73,024,147 74,840,846 72,924,178 75,822,713 Effect of potential common shares 235,125 — 692,659 812,250 Weighted-average shares: diluted 73,259,272 74,840,846 73,616,837 76,634,963 Income/(loss) per share: basic $ 0.45 $ (0.04 ) $ 0.48 $ (0.05 ) Income/(loss) per share: diluted $ 0.45 $ (0.04 ) $ 0.47 $ (0.05 ) For the nine September 30, 2022 not three nine September 30, 2022 three nine September 30, 2022 For the three nine September 30, 2021 Three Months Ended September 30, Nine Months Ended September 30, 2021 2021 Warrants 1,047,296 — Stock options 150,000 153,055 Restricted stock units 204,591 181,730

Note 10 - Commitments and Conti

Note 10 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	10. Commitments and Contingencies From time to time, we may not Purchase Commitments In the course of our business, the Company regularly enters into agreements with third not September 30, 2022

Note 11 - Related Party Transac

Note 11 - Related Party Transactions	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	11. Related Party Transactions Board of Directors and Outside Counsel A former member of the Company’s Board of Directors who did not 2021 not three September 30, 2022 2021 nine September 30, 2022 nine September 30, 2021 September 30, 2022 Real Estate Leases On May 26, 2017, ten 31 62 nd first sixty-three first six first sixty-fourth first second five three nine September 30, 2022

Note 12 - Revenues by Geographi

Note 12 - Revenues by Geographic Region	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	12. Revenues by Geographic Region Revenues by geographic region were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 United States $ 10,925,562 $ 2,475,689 $ 33,180,163 $ 5,387,145 International Asia-Pacific 8,946,221 — 13,875,644 — Canada 35,120,212 2,370,483 35,120,212 12,926,061 Europe, Middle East and Africa (EMEA) 16,255,715 — 16,278,035 — Other 963,417 — 963,417 — Total International 61,285,565 2,370,483 66,237,308 12,926,061 Total revenues $ 72,211,127 $ 4,846,172 $ 99,417,471 $ 18,313,206

Note 13 - Income Taxes

Note 13 - Income Taxes	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Income Tax Disclosure [Text Block]	13. Income Taxes The Company’s provision for income taxes consists of federal and state taxes, as applicable, in amounts necessary to align the Company’s year-to-date tax provision with the effective rate that it expects to achieve for the full year. Each quarter the Company updates its estimate of the annual effective tax rate and records cumulative adjustments as necessary. For the three September 30, 2022 2021 For the nine September 30, 2022 2021 The effective tax rate for the three September 30, 2022 three September 30, 2021 three September 30, 2022 162 The effective tax rate for the nine September 30, 2022 nine September 30, 2021 nine September 30, 2022 162 The Inflation Reduction Act of 2022 August 16, 2022. three $1 not

Note 14 - Equity

Note 14 - Equity	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	14. The tables below present changes in stockholders' equity for the three nine September 30, 2022 2021 Common Stock Additional Paid-in Accumulated Other Comprehensive Total Stockholders' Shares Amount Capital Deficit Income Equity Balances at June 30, 2022 73,024,147 $ 7,302 $ 232,942,666 $ (93,181,114 ) $ — $ 139,768,854 Net income — — — 33,040,588 — 33,040,588 Stock-based compensation — — 328,685 — — 328,685 Balances at September 30, 2022 73,024,147 $ 7,302 $ 233,271,351 $ (60,140,526 ) $ — $ 173,138,127 Common Stock Additional Paid-in Accumulated Other Comprehensive Total Stockholders' Shares Amount Capital Deficit Income Equity Balances at December 31, 2021 73,543,602 $ 7,354 $ 226,070,308 $ (51,763,255 ) $ — $ 174,314,407 Net income — — — 34,716,600 — 34,716,600 Repurchase of common stock (1,474,781 ) (147 ) — (10,149,557 ) — (10,149,704 ) Payment of common stock tendered for employee stock-based compensation tax obligations (1,973 ) — (12,533 ) — — (12,533 ) Issuance of common stock upon vesting of RSUs 132,396 13 (13 ) — — — Issuance of common stock upon exercise of warrants 824,903 82 6,120,696 — — 6,120,778 Cash dividend ($0.45 per share) — — — (32,944,314 ) — (32,944,314 ) Stock-based compensation — — 1,092,893 — — 1,092,893 Balances at September 30, 2022 73,024,147 $ 7,302 $ 233,271,351 $ (60,140,526 ) $ — $ 173,138,127 Common Stock Additional Paid-in Accumulated Other Comprehensive Total Stockholders' Shares Amount Capital Deficit Income Equity Balances at June 30, 2021 75,389,417 $ 7,539 $ 225,678,876 $ (108,965,453 ) $ — $ 116,720,962 Net loss — — — (3,113,358 ) — (3,113,358 ) Repurchase of common stock (1,110,763 ) (111 ) — (7,134,577 ) — (7,134,688 ) Payment of common stock tendered for employee stock-based compensation tax obligations (25,203 ) (2 ) (160,554 ) — — (160,556 ) Issuance of common stock upon vesting of RSUs 53,334 5 (5 ) — — — Stock-based compensation — — 243,502 — — 243,502 Balances at September 30, 2021 74,306,785 $ 7,431 $ 225,761,819 $ (119,213,388 ) $ — $ 106,555,862 Common Stock Additional Paid-in Accumulated Other Comprehensive Total Stockholders' Shares Amount Capital Deficit Income Equity Balances at December 31, 2020 77,195,704 $ 7,720 $ 224,978,430 $ (95,192,881 ) $ — $ 129,793,269 Net loss — — — (3,756,262 ) — (3,756,262 ) Repurchase of common stock (3,024,690 ) (302 ) — (20,264,245 ) — (20,264,547 ) Payment of common stock tendered for employee stock-based compensation tax obligations (27,105 ) (3 ) (173,915 ) — — (173,918 ) Issuance of common stock upon vesting of RSUs 162,876 16 (16 ) — — — Stock-based compensation — — 957,320 — — 957,320 Balances at September 30, 2021 74,306,785 $ 7,431 $ 225,761,819 $ (119,213,388 ) $ — $ 106,555,862 On August 2, 2021, may December 31, 2023. fourth 2021. may may 10b5 1 1934, nine September 30, 2022 three September 30, 2022. Prior to the effective date of the New Repurchase Authorization, the Company repurchased shares under a program that was announced in March 2020. three September 30, 2021 nine September 30, 2021 On May 5, 2022, June 2, 2022 May 17, 2022.

Note 15 - Leases

Note 15 - Leases	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	15. The Company leases its Corvallis, Oregon, facilities and office space under an operating lease, which was signed on November 3, 2017 January 1, 2018. December 31, 2019 two one two three second 2019, first December 31, 2021. second 2021, second December 31, 2024. second second 2021. On May 26, 2017 ten no Operating lease costs totaled $0.2 million and $0.1 million for the three September 30, 2022 2021 nine September 30, 2022 2021 three September 30, 2022 2021 nine September 30, 2022 2021 September 30, 2022 Future cash flows under operating leases as of September 30, 2022 2022 $ 110,340 2023 669,048 2024 678,627 2025 406,994 2026 409,971 Thereafter 165,916 Total undiscounted cash flows under leases 2,440,896 Less: Imputed interest (224,813 ) Present value of lease liabilities $ 2,216,083 As of September 30, 2022

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers 606” September 30, 2022 Note 3 five five September 30, 2022 not three Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606. Contract modifications may not The Company’s performance obligations are satisfied over time as work progresses or at a point in time. All of the Company’s revenue related to current research and development performance obligations is recognized over time, because the customer simultaneously receives and consumes the benefits provided by the services as the Company performs these services. The Company recognizes revenue related to these services based on the progress toward complete satisfaction of the performance obligation and measures this progress under an input method, which is based on the Company’s cost incurred relative to total estimated costs. Under this method, progress is measured based on the cost of resources consumed (i.e., cost of third third Contract Balances The timing of revenue recognition, billings and cash collections may September 30, 2022 nine September 30, 2022
Stockholders' Equity, Policy [Policy Text Block]	Repurchase of shares When shares recognized as equity are repurchased, the amount of the consideration paid, which includes directly attributable costs, is recognized as a deduction from equity. The excess of the purchase price above par value of repurchased shares that are retired is presented as an increase to accumulated deficit (or a reduction of retained earnings, if any).

Note 4 - Inventory (Tables)

Note 4 - Inventory (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Inventory, Current [Table Text Block]	As of September 30, 2022 December 31, 2021 Raw materials $ 22,047 $ 22,047 Work in-process 25,075,163 17,453,358 Finished goods 6,164,136 2,034,974 Inventory $ 31,261,346 $ 19,510,379

Note 5 - Property, Plant and _2

Note 5 - Property, Plant and Equipment (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Property, Plant and Equipment [Table Text Block]	As of September 30, 2022 December 31, 2021 Leasehold improvements $ 2,420,028 $ 2,420,028 Computer equipment 471,286 511,062 Furniture and fixtures 347,045 377,859 Operating lease right-of-use assets 3,678,647 3,678,647 6,917,006 6,987,596 Less - accumulated depreciation and amortization (4,937,489 ) (4,621,639 ) Property, plant and equipment, net $ 1,979,517 $ 2,365,957

Note 6 - Accrued Expenses and_2

Note 6 - Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Accrued Expenses and Other Current Liabilities [Table Text Block]	As of September 30, 2022 December 31, 2021 Deferred revenue $ 10,129,667 $ 3,764,696 Compensation 1,997,717 2,811,700 Research and development vendor costs 1,107,791 256,397 Professional fees 900,205 527,026 Other 852,370 938,082 Lease liability, current portion 519,198 466,830 Inventory 380,411 488,081 Accrued expenses and other current liabilities $ 15,887,359 $ 9,252,812

Note 8 - Fair Value of Financ_2

Note 8 - Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Fair Value Measurements of Level 3 liability-classified warrant Warrant liability at December 31, 2021 $ 6,521,441 Decrease in fair value of Warrant liability (400,663 ) Exercise of Warrant (6,120,778 ) Warrant liability at September 30, 2022 $ -

Note 9 - Per Share Data (Tables

Note 9 - Per Share Data (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Net income/(loss) for basic earnings per share $ 33,040,588 $ (3,113,358 ) $ 34,716,600 $ (3,756,262 ) Less: Change in fair value of warrants — — 400,663 294,548 Net income/(loss), adjusted for change in fair value of warrants for diluted earnings per share $ 33,040,588 $ (3,113,358 ) $ 34,315,937 $ (4,050,810 ) Weighted-average shares 73,024,147 74,840,846 72,924,178 75,822,713 Effect of potential common shares 235,125 — 692,659 812,250 Weighted-average shares: diluted 73,259,272 74,840,846 73,616,837 76,634,963 Income/(loss) per share: basic $ 0.45 $ (0.04 ) $ 0.48 $ (0.05 ) Income/(loss) per share: diluted $ 0.45 $ (0.04 ) $ 0.47 $ (0.05 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2021 2021 Warrants 1,047,296 — Stock options 150,000 153,055 Restricted stock units 204,591 181,730

Note 12 - Revenues by Geograp_2

Note 12 - Revenues by Geographic Region (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Revenue from External Customers by Geographic Areas [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 United States $ 10,925,562 $ 2,475,689 $ 33,180,163 $ 5,387,145 International Asia-Pacific 8,946,221 — 13,875,644 — Canada 35,120,212 2,370,483 35,120,212 12,926,061 Europe, Middle East and Africa (EMEA) 16,255,715 — 16,278,035 — Other 963,417 — 963,417 — Total International 61,285,565 2,370,483 66,237,308 12,926,061 Total revenues $ 72,211,127 $ 4,846,172 $ 99,417,471 $ 18,313,206

Note 14 - Equity (Tables)

Note 14 - Equity (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Stockholders Equity [Table Text Block]	Common Stock Additional Paid-in Accumulated Other Comprehensive Total Stockholders' Shares Amount Capital Deficit Income Equity Balances at June 30, 2022 73,024,147 $ 7,302 $ 232,942,666 $ (93,181,114 ) $ — $ 139,768,854 Net income — — — 33,040,588 — 33,040,588 Stock-based compensation — — 328,685 — — 328,685 Balances at September 30, 2022 73,024,147 $ 7,302 $ 233,271,351 $ (60,140,526 ) $ — $ 173,138,127 Common Stock Additional Paid-in Accumulated Other Comprehensive Total Stockholders' Shares Amount Capital Deficit Income Equity Balances at December 31, 2021 73,543,602 $ 7,354 $ 226,070,308 $ (51,763,255 ) $ — $ 174,314,407 Net income — — — 34,716,600 — 34,716,600 Repurchase of common stock (1,474,781 ) (147 ) — (10,149,557 ) — (10,149,704 ) Payment of common stock tendered for employee stock-based compensation tax obligations (1,973 ) — (12,533 ) — — (12,533 ) Issuance of common stock upon vesting of RSUs 132,396 13 (13 ) — — — Issuance of common stock upon exercise of warrants 824,903 82 6,120,696 — — 6,120,778 Cash dividend ($0.45 per share) — — — (32,944,314 ) — (32,944,314 ) Stock-based compensation — — 1,092,893 — — 1,092,893 Balances at September 30, 2022 73,024,147 $ 7,302 $ 233,271,351 $ (60,140,526 ) $ — $ 173,138,127 Common Stock Additional Paid-in Accumulated Other Comprehensive Total Stockholders' Shares Amount Capital Deficit Income Equity Balances at June 30, 2021 75,389,417 $ 7,539 $ 225,678,876 $ (108,965,453 ) $ — $ 116,720,962 Net loss — — — (3,113,358 ) — (3,113,358 ) Repurchase of common stock (1,110,763 ) (111 ) — (7,134,577 ) — (7,134,688 ) Payment of common stock tendered for employee stock-based compensation tax obligations (25,203 ) (2 ) (160,554 ) — — (160,556 ) Issuance of common stock upon vesting of RSUs 53,334 5 (5 ) — — — Stock-based compensation — — 243,502 — — 243,502 Balances at September 30, 2021 74,306,785 $ 7,431 $ 225,761,819 $ (119,213,388 ) $ — $ 106,555,862 Common Stock Additional Paid-in Accumulated Other Comprehensive Total Stockholders' Shares Amount Capital Deficit Income Equity Balances at December 31, 2020 77,195,704 $ 7,720 $ 224,978,430 $ (95,192,881 ) $ — $ 129,793,269 Net loss — — — (3,756,262 ) — (3,756,262 ) Repurchase of common stock (3,024,690 ) (302 ) — (20,264,245 ) — (20,264,547 ) Payment of common stock tendered for employee stock-based compensation tax obligations (27,105 ) (3 ) (173,915 ) — — (173,918 ) Issuance of common stock upon vesting of RSUs 162,876 16 (16 ) — — — Stock-based compensation — — 957,320 — — 957,320 Balances at September 30, 2021 74,306,785 $ 7,431 $ 225,761,819 $ (119,213,388 ) $ — $ 106,555,862

Note 15 - Leases (Tables)

Note 15 - Leases (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	2022 $ 110,340 2023 669,048 2024 678,627 2025 406,994 2026 409,971 Thereafter 165,916 Total undiscounted cash flows under leases 2,440,896 Less: Imputed interest (224,813 ) Present value of lease liabilities $ 2,216,083

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Details Textual) $ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($)
Revenue, Remaining Performance Obligation, Amount	$ 82.9
Contract with Customer, Asset, after Allowance for Credit Loss, Total	46.3
Contract with Customer, Liability, Revenue Recognized	$ 3.5

Note 3 - Procurement Contract_2

Note 3 - Procurement Contracts and Research Agreements (Details Textual) $ in Thousands							3 Months Ended			9 Months Ended		12 Months Ended
	Oct. 31, 2022 USD ($)	Sep. 28, 2022 USD ($)	May 12, 2022 USD ($)	Jan. 13, 2021 USD ($)	Apr. 03, 2020 USD ($)	Sep. 10, 2018 USD ($)	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Jul. 31, 2019 USD ($)
Contract with Customer, Liability, Revenue Recognized										$ 3,500
The 19C BARDA Contract [Member]
Number of Courses to Be Delivered						1,488,000
Government Contract, Value of Award							$ 602,500			602,500
Government Contract, Base Period, Value of Award for Delivery and Support Activities						$ 51,700	51,700			$ 51,700
Base Period of Performance (Year)										5 years
Government Contract Value Related To Exercised Options										$ 268,900
Government Contract, Value, Payments Currently Specified as Unexercised Options										$ 281,900
Base Period of Performance, Exercise of Options, Term (Year)										10 years
Government Contract, Base Period, Value of Award for Delivery and Support Activities, Delivery of Courses						$ 11,100
Government Contract, Base Period, Number of Deliveries						35,700
Government Contract, Base Period, Value of Award for Delivery and Support Activities, Manufacture of Courses						$ 8,000
Government Contract, Base Period, Value of Award for Delivery and Support Activities, Advanced Development						32,000
Government Contract, Base Period, Value of Award for Delivery and Support Activities, Supportive Procurement Activities						$ 600
Proceeds from Delivery of Courses										$ 11,100
Number of Courses Delivered										35,700
Proceeds from Other Base Period Activities										$ 17,100
Government Contract, Value of Unexercised Options, Supportive Procurement Activities							5,600			5,600
The 19C BARDA Contract [Member] | Transferred over Time [Member]
Contract with Customer, Liability, Revenue Recognized							2,700		$ 1,100	4,600	$ 2,800
The 19C BARDA Contract [Member] | Transferred at Point in Time [Member]
Contract with Customer, Liability, Revenue Recognized										7,200
The 19C BARDA Contract [Member] | IV TPOXX [Member]
Government Contract, Base Period, Number of Courses Manufactured						20,000
Government Contract Option Value Of Award For Delivery and Support Activities Manufacture of Courses													$ 10,200
Government Contract, Value, Payments Related to Exercised Options, Funding of Post-Marketing Activities							$ 3,600			$ 3,600
Number of Manufacturing Steps							2			2
The 19C BARDA Contract [Member] | IV BDS [Member]
Government Contract, Base Period, Value of Award for Delivery and Support Activities, Manufacture of Courses						$ 3,200
Proceeds from the Manufacture of Courses										$ 3,200
Proceeds from the Delivery of Courses										4,300
Contract with Customer, Liability, Total							$ 10,200			10,200		$ 3,200
Government Contract, Value, Payments Currently Specified as Unexercised Options, Manufacture of Courses							20,500			20,500
Government Contract, Value of Courses Manufactured Upon Exercise of Options							$ 20,500			$ 20,500
Government Contract, Number of Options for Manufacture of Product							3			3
Government Contract, Courses Manufactured Upon Exercise of Options							64,000			64,000
The 19C BARDA Contract [Member] | IV FDP Containing IV BDS [Member]
Contract with Customer, Liability, Total							$ 300			$ 300
Contract with Customer, Liability, Revenue Recognized										2,900
The 19C BARDA Contract [Member] | Oral TPOXX [Member]
Government Contract, Base Period, Value of Award for Delivery and Support Activities, Manufacture of Courses										25,600
Number of Courses Delivered													726,140
Government Contract, Value, Payments Related to Exercised Options, Procurement of Raw Materials							225,100			225,100			$ 11,200
Government Contract, Value, Payments Related to Exercised Options, Delivery of Courses													213,900
Government Contract, Value, Payments Related to Exercised Options, Funding of Post-Marketing Activities													$ 14,600
Proceeds from Payments Received for Post-marketing Activities										8,100
Government Contract, Value, Payments Related to Unexercised Options, Delivery of Courses							225,100			225,100
The 19C BARDA Contract [Member] | IV FDP [Member]
Government Contract, Value, Payments Currently Specified as Unexercised Options, Manufacture of Courses							$ 51,200			$ 51,200
Government Contract, Number of Options for Manufacture of Product							3			3
Government Contract, Courses Manufactured Upon Exercise of Options							64,000			64,000
The 19C BARDA Contract [Member] | Maximum [Member]
Number of Courses to Be Delivered						212,000
IC BARDA [Member] | Transferred at Point in Time [Member]
Contract with Customer, Liability, Revenue Recognized							$ 0		0		0
U.S. Department of Defense (“DoD”) [Member] | Oral TPOXX [Member]
Government Contract, Value, Payments Currently Specified as Unexercised Options		$ 5,500	$ 3,800
Contract with Customer, Liability, Revenue Recognized								$ 3,600
Government Contract, Value Ordered		$ 5,200	$ 3,600
Government Contract, Value, Option Exercised							3,800
International Procurement [Member]
Contract with Customer, Liability, Revenue Recognized							61,300			$ 66,200
International Procurement [Member] | Oral TPOXX [Member]
Contract with Customer, Liability, Revenue Recognized										66,000
International Procurement [Member] | Oral TPOXX [Member] | Subsequent Event [Member]
Government Contract, Value of Award	$ 77,000
Government Contract, Value, Payments Currently Specified as Unexercised Options	6,000
International Procurement [Member] | Oral TPOXX [Member] | Subsequent Event [Member] | CANADA
Government Contract, Value of Award	39,000
International Procurement [Member] | Oral TPOXX [Member] | Subsequent Event [Member] | Europe, Asia Pacific and the Middle East [Member]
Government Contract, Value of Award	$ 38,000
Meridian Contract [Member]
Contract with Customer, Liability, Revenue Recognized									2,300		12,700
Meridian Contract [Member] | Oral TPOXX [Member]
Government Contract, Value of Award				$ 33,000
Contract with Customer, Liability, Revenue Recognized							35,000					10,000
Government Contract, Term (Year)				5 years
Government Contract, Increased Value of Award				$ 45,000
Government Contract, Award, Target Delivery Amount							0			0
Canadian Contract [Member] | Meridian Medical Technologies [Member]
Contract with Customer, Liability, Revenue Recognized												$ 4,000
Government Contract, Term (Year)					4 years
Government Contract, Award, Target Delivery Amount							4,000			4,000
Other Commitment, Total					$ 14,000
Government Contract, Unexercised Options										6,000
The PEP Label Expansion R & D Contract with the Department of Defense [Member]
Government Contract, Value of Award														$ 19,500
Contract with Customer, Liability, Revenue Recognized							4,200		$ 1,300	13,100	$ 2,000
Government Contract, Increased Value of Award														27,000
Government Contract, Initial Award														$ 12,400
Contract With Customer Liability Remaining Revenue To Be Recognized							$ 11,200			$ 11,200

Note 4 - Inventory - Inventory

Note 4 - Inventory - Inventory (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Raw materials	$ 22,047	$ 22,047
Work in-process	25,075,163	17,453,358
Finished goods	6,164,136	2,034,974
Inventory	$ 31,261,346	$ 19,510,379

Note 5 - Property, Plant and _3

Note 5 - Property, Plant and Equipment (Details Textual) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Depreciation, Depletion and Amortization, Total	$ 386,440	$ 393,667

Note 5 - Property, Plant and _4

Note 5 - Property, Plant and Equipment - Property, Plant and Equipment (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Property, plant and equipment, gross	$ 6,917,006	$ 6,987,596
Less - accumulated depreciation and amortization	(4,937,489)	(4,621,639)
Property, plant and equipment, net	1,979,517	2,365,957
Other Assets [Member]
Property, plant and equipment, gross	3,678,647	3,678,647
Leasehold Improvements [Member]
Property, plant and equipment, gross	2,420,028	2,420,028
Computer Equipment [Member]
Property, plant and equipment, gross	471,286	511,062
Furniture and Fixtures [Member]
Property, plant and equipment, gross	$ 347,045	$ 377,859

Note 6 - Accrued Expenses and_3

Note 6 - Accrued Expenses and Other Current Liabilities - Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Deferred revenue	$ 10,129,667	$ 3,764,696
Compensation	1,997,717	2,811,700
Research and development vendor costs	1,107,791	256,397
Professional fees	900,205	527,026
Other	852,370	938,082
Inventory	380,411	488,081
Accrued expenses and other current liabilities	15,887,359	9,252,812
Accrued Expenses and Other Current Liabilities [Member]
Lease liability, current portion	$ 519,198	$ 466,830

Note 7 - Financial Instruments

Note 7 - Financial Instruments (Details Textual) $ / shares in Units, shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Jun. 30, 2022	Dec. 31, 2021 USD ($) shares	Sep. 02, 2016 USD ($) $ / shares shares
(Gain) Loss on Change in Fair Value of Warrant Liability	$ 0	$ 1,066,522	$ (400,663)	$ (294,548)
Warrants and Rights Outstanding	$ 0		0			$ 6,521,441
The 2016 Warrant [Member]
Class of Warrant or Right Outstanding, Common Stock Value Used to Determine Number of Shares Called							$ 4,000,000
Class of Warrant or Right Outstanding, Common Stock Price Per Share Used to Determine Number of Shares Called (in dollars per share) | $ / shares							$ 2.29
Warrants and Rights Outstanding, Term (Year)							10 years
Class of Warrant or Right, Subscription Price of Warrants or Rights (in dollars per share) | $ / shares							$ 1.50
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares							$ 1.50
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares						1	2.7
(Gain) Loss on Change in Fair Value of Warrant Liability			$ 400,000
Warrants and Rights Outstanding						$ 6,500,000
The 2016 Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input					0	0
The 2016 Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input						0.0121
The 2016 Warrant [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input						4.7
The 2016 Warrant [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input						0.55

Note 8 - Fair Value of Financ_3

Note 8 - Fair Value of Financial Instruments (Details Textual) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Fair Value, Inputs, Level 1 [Member]
Cash and Cash Equivalents, Fair Value Disclosure	$ 100	$ 100
Fair Value, Inputs, Level 2 [Member]
Cash and Cash Equivalents, Fair Value Disclosure	$ 35,100	$ 0

Note 8 - Fair Value of Financ_4

Note 8 - Fair Value of Financial Instruments - Changes in the Liability-classified Warrant Measured at Fair Value (Details)	9 Months Ended
	Sep. 30, 2022 USD ($)
Warrant liability	$ 6,521,441
Decrease in fair value of Warrant liability	(400,663)
Exercise of Warrant	(6,120,778)
Warrant liability	$ 0

Note 9 - Per Share Data (Detail

Note 9 - Per Share Data (Details Textual) - shares	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	32,180	12,901

Note 9 - Per Share Data - Recon

Note 9 - Per Share Data - Reconciliation of the Basic and Diluted Loss Per Share (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Net income (loss)	$ 33,040,588	$ (3,113,358)	$ 34,716,600	$ (3,756,262)
Less: Change in fair value of warrants	0	0	400,663	294,548
Net income/(loss), adjusted for change in fair value of warrants for diluted earnings per share	$ 33,040,588	$ (3,113,358)	$ 34,315,937	$ (4,050,810)
Weighted average shares outstanding: basic (in shares)	73,024,147	74,840,846	72,924,178	75,822,713
Effect of potential common shares (in shares)	235,125	0	692,659	812,250
Weighted average shares outstanding: diluted (in shares)	73,259,272	74,840,846	73,616,837	76,634,963
Basic income/(loss) per share (in dollars per share)	$ 0.45	$ (0.04)	$ 0.48	$ (0.05)
Diluted income/(loss) per share (in dollars per share)	$ 0.45	$ (0.04)	$ 0.47	$ (0.05)

Note 9 - Per Share Data - Antid

Note 9 - Per Share Data - Antidilutive Securities Excluded from Computation (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Antidilutive securities (in shares)	32,180		12,901
Warrant [Member]
Antidilutive securities (in shares)		1,047,296		0
Share-Based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)		150,000		153,055
Restricted Stock Units (Stock Settled) [Member]
Antidilutive securities (in shares)		204,591		181,730

Note 10 - Commitments and Con_2

Note 10 - Commitments and Contingencies (Details Textual) $ in Millions	Sep. 30, 2022 USD ($)
Purchase Commitment, Remaining Minimum Amount Committed	$ 21.8

Note 11 - Related Party Trans_2

Note 11 - Related Party Transactions (Details Textual)		3 Months Ended		9 Months Ended
	May 26, 2017 USD ($) ft²	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)
Outside Counsel [Member]
Legal Fees		$ 0	$ 0	$ 0	$ 100,000
Accounts Payable, Related Parties		0		0
MacAndrews and Forbes Incorporated [Member] | The New HQ Lease [Member]
Lessee, Operating Lease, Term of Contract (Year)	10 years
Area of Real Estate Property (Square Foot) | ft²	3,200
Monthly Rent During Initial Period	$ 25,333
Monthly Rent, Initial Period (Month)	63 months
Monthly Rent After Initial Period	$ 29,333
Monthly Facility Fee, Second Year	$ 3,333
Monthly Facility Fee, Yearly Rate Increase After Second Year	5%
Monthly Facility Fee, Final Year	$ 4,925
Operating Lease, Expense		$ 100,000		$ 300,000

Note 12 - Revenues by Geograp_3

Note 12 - Revenues by Geographic Region - Revenues by Geographic Region (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Total revenues	$ 72,211,127	$ 4,846,172	$ 99,417,471	$ 18,313,206
UNITED STATES
Total revenues	10,925,562	2,475,689	33,180,163	5,387,145
Asia Pacific [Member]
Total revenues	8,946,221	0	13,875,644	0
CANADA
Total revenues	35,120,212	2,370,483	35,120,212	12,926,061
EMEA [Member]
Total revenues	16,255,715	0	16,278,035	0
Other [Member]
Total revenues	963,417	0	963,417	0
Non-US [Member]
Total revenues	$ 61,285,565	$ 2,370,483	$ 66,237,308	$ 12,926,061

Note 13 - Income Taxes (Details

Note 13 - Income Taxes (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income (Loss) Attributable to Parent, before Tax, Total	$ 43,100,000	$ (4,000,000)	$ 45,300,000	$ (4,600,000)
Income Tax Expense (Benefit), Total	$ 10,091,420	$ (870,801)	$ 10,543,595	$ (805,328)
Effective Income Tax Rate Reconciliation, Percent, Total	23.40%	21.90%	23.30%	17.70%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21%		21%

Note 14 - Equity (Details Textu

Note 14 - Equity (Details Textual) - USD ($) $ / shares in Units, shares in Thousands		3 Months Ended		9 Months Ended
	May 05, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Aug. 02, 2021
Stock Repurchase Program, Authorized Amount						$ 50,000,000
Stock Repurchased During Period, Shares (in shares)		0		1,500
Stock Repurchased During Period, Value			$ 7,134,688	$ 10,149,704	$ 20,264,547
Special Dividend [Member]
Common Stock, Dividends, Per Share, Declared (in dollars per share)	$ 0.45
Dividends, Total	$ 32,900,000
New Repurchase Authorization [Member]
Stock Repurchase Program, Authorized Amount						$ 50,000,000
Stock Repurchased During Period, Shares (in shares)			1,100		3,000
Stock Repurchased During Period, Value			$ 7,100,000		$ 20,300,000

Note 14 - Equity - Changes in S

Note 14 - Equity - Changes in Stockholders' Equity (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Balances	$ 139,768,854	$ 116,720,962	$ 174,314,407	$ 129,793,269
Net income (loss)	33,040,588	(3,113,358)	34,716,600	(3,756,262)
Stock-based compensation	$ 328,685	243,502	$ 1,092,893	957,320
Repurchase of common stock (in shares)	0		(1,500,000)
Repurchase of common stock		(7,134,688)	$ (10,149,704)	(20,264,547)
Payment of common stock tendered for employee stock-based compensation tax obligations		(160,556)	(12,533)	(173,918)
Issuance of common stock upon vesting of RSUs		0	0	0
Issuance of common stock upon exercise of warrants			6,120,778
Cash dividend ($0.45 per share)			(32,944,314)
Net income (loss)	$ 33,040,588	(3,113,358)	34,716,600	(3,756,262)
Balances	$ 173,138,127	$ 106,555,862	$ 173,138,127	$ 106,555,862
Common Stock [Member]
Balances (in shares)	73,024,147	75,389,417	73,543,602	77,195,704
Balances	$ 7,302	$ 7,539	$ 7,354	$ 7,720
Net income (loss)	0	0	0	0
Stock-based compensation	0	$ 0	$ 0	$ 0
Repurchase of common stock (in shares)		(1,110,763)	(1,474,781)	(3,024,690)
Repurchase of common stock		$ (111)	$ (147)	$ (302)
Payment of common stock tendered for employee stock-based compensation tax obligations (in shares)		(25,203)	(1,973)	(27,105)
Payment of common stock tendered for employee stock-based compensation tax obligations		$ (2)	$ 0	$ (3)
Issuance of common stock upon vesting of RSUs (in shares)		53,334	132,396	162,876
Issuance of common stock upon vesting of RSUs		$ 5	$ 13	$ 16
Issuance of common stock upon exercise of warrants (in shares)			824,903
Issuance of common stock upon exercise of warrants			$ 82
Cash dividend ($0.45 per share)			0
Net income (loss)	$ 0	$ 0	$ 0	$ 0
Balances (in shares)	73,024,147	74,306,785	73,024,147	74,306,785
Balances	$ 7,302	$ 7,431	$ 7,302	$ 7,431
Additional Paid-in Capital [Member]
Balances	232,942,666	225,678,876	226,070,308	224,978,430
Net income (loss)	0	0	0	0
Stock-based compensation	328,685	243,502	1,092,893	957,320
Repurchase of common stock		0	0	0
Payment of common stock tendered for employee stock-based compensation tax obligations		(160,554)	(12,533)	(173,915)
Issuance of common stock upon vesting of RSUs		(5)	(13)	(16)
Issuance of common stock upon exercise of warrants			6,120,696
Cash dividend ($0.45 per share)			0
Net income (loss)	0	0	0	0
Balances	233,271,351	225,761,819	233,271,351	225,761,819
Retained Earnings [Member]
Balances	(93,181,114)	(108,965,453)	(51,763,255)	(95,192,881)
Net income (loss)	33,040,588	(3,113,358)	34,716,600	(3,756,262)
Stock-based compensation	0	0	0	0
Repurchase of common stock		(7,134,577)	(10,149,557)	(20,264,245)
Payment of common stock tendered for employee stock-based compensation tax obligations		0	0	0
Issuance of common stock upon vesting of RSUs		0	0	0
Issuance of common stock upon exercise of warrants			0
Cash dividend ($0.45 per share)			(32,944,314)
Net income (loss)	33,040,588	(3,113,358)	34,716,600	(3,756,262)
Balances	(60,140,526)	(119,213,388)	(60,140,526)	(119,213,388)
AOCI Attributable to Parent [Member]
Balances	0	0	0	0
Net income (loss)	0	0	0	0
Stock-based compensation	0	0	0	0
Repurchase of common stock		0	0	0
Payment of common stock tendered for employee stock-based compensation tax obligations		0	0	0
Issuance of common stock upon vesting of RSUs		0	0	0
Issuance of common stock upon exercise of warrants			0
Cash dividend ($0.45 per share)			0
Net income (loss)	0	0	0	0
Balances	$ 0	$ 0	$ 0	$ 0

Note 15 - Leases (Details Textu

Note 15 - Leases (Details Textual)	3 Months Ended			9 Months Ended		12 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Jun. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Dec. 31, 2019	May 26, 2017 ft²
Operating Lease, Cost	$ 200,000	$ 100,000		$ 500,000	$ 400,000
Operating Lease, Payments	$ 200,000	$ 100,000		$ 500,000	$ 400,000
Operating Lease, Weighted Average Remaining Lease Term (Year)	3 years 10 months 17 days			3 years 10 months 17 days
Operating Lease, Weighted Average Discount Rate, Percent	4.53%			4.53%
Operating Lease, Liability, Total	$ 2,216,083			$ 2,216,083
Other Liabilities [Member]
Operating Lease, Liability, Total	$ 1,700,000			$ 1,700,000
Facilities and Office Space in Corvallis Oregon [Member]
Lessee, Operating Lease, First Renewal Term (Year)						2 years
Lessee, Operating Lease, Second Renewal Term (Year)						3 years
Increase (Decrease) in Operating Lease Liability			$ 700,000
The New HQ Lease [Member] | MacAndrews and Forbes Incorporated [Member]
Lessee, Operating Lease, Term of Contract (Year)							10 years
Area of Real Estate Property (Square Foot) | ft²							3,200

Note 15 - Leases - Future Undis

Note 15 - Leases - Future Undiscounted Cash Flows Under Operating Leases (Details)	Sep. 30, 2022 USD ($)
2022	$ 110,340
2023	669,048
2024	678,627
2025	406,994
2026	409,971
Thereafter	165,916
Total undiscounted cash flows under leases	2,440,896
Less: Imputed interest	(224,813)
Present value of lease liabilities	$ 2,216,083